Literature DB >> 19783986

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

Giulia Fontemaggi1, Stefania Dell'Orso, Daniela Trisciuoglio, Tal Shay, Elisa Melucci, Francesco Fazi, Irene Terrenato, Marcella Mottolese, Paola Muti, Eytan Domany, Donatella Del Bufalo, Sabrina Strano, Giovanni Blandino.   

Abstract

ID4 (inhibitor of DNA binding 4) is a member of a family of proteins that function as dominant-negative regulators of basic helix-loop-helix transcription factors. Growing evidence links ID proteins to cell proliferation, differentiation and tumorigenesis. Here we identify ID4 as a transcriptional target of gain-of-function p53 mutants R175H, R273H and R280K. Depletion of mutant p53 protein severely impairs ID4 expression in proliferating tumor cells. The protein complex mutant p53-E2F1 assembles on specific regions of the ID4 promoter and positively controls ID4 expression. The ID4 protein binds to and stabilizes mRNAs encoding pro-angiogenic factors IL8 and GRO-alpha. This results in the increase of the angiogenic potential of cancer cells expressing mutant p53. These findings highlight the transcriptional axis mutant p53, E2F1 and ID4 as a still undefined molecular mechanism contributing to tumor neo-angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19783986     DOI: 10.1038/nsmb.1669

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  52 in total

1.  Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1.

Authors:  J Sampath; D Sun; V J Kidd; J Grenet; A Gandhi; L H Shapiro; Q Wang; G P Zambetti; J D Schuetz
Journal:  J Biol Chem       Date:  2001-08-01       Impact factor: 5.157

2.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

3.  Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.

Authors:  Silvia Di Agostino; Sabrina Strano; Velia Emiliozzi; Valentina Zerbini; Marcella Mottolese; Ada Sacchi; Giovanni Blandino; Giulia Piaggio
Journal:  Cancer Cell       Date:  2006-09       Impact factor: 31.743

4.  A new model of cell cycle-regulated transcription: repression of the cyclin A promoter by CDF-1 and anti-repression by E2F.

Authors:  N Liu; F C Lucibello; K Engeland; R Müller
Journal:  Oncogene       Date:  1998-06-11       Impact factor: 9.867

Review 5.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Authors:  A Sigal; V Rotter
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

6.  An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control.

Authors:  A Gualberto; K Aldape; K Kozakiewicz; T D Tlsty
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

7.  Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts.

Authors:  D Lyden; A Z Young; D Zagzag; W Yan; W Gerald; R O'Reilly; B L Bader; R O Hynes; Y Zhuang; K Manova; R Benezra
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

8.  Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.

Authors:  G Bossi; E Lapi; S Strano; C Rinaldo; G Blandino; A Sacchi
Journal:  Oncogene       Date:  2006-01-12       Impact factor: 9.867

9.  Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis.

Authors:  Maresa Caunt; Liang Hu; Thomas Tang; Peter C Brooks; Sherif Ibrahim; Simon Karpatkin
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

10.  Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.

Authors:  G Blandino; A J Levine; M Oren
Journal:  Oncogene       Date:  1999-01-14       Impact factor: 9.867

View more
  96 in total

Review 1.  MicroRNAs, wild-type and mutant p53: more questions than answers.

Authors:  Matthew Jones; Ashish Lal
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

2.  Mutant p53 cooperates with ETS2 to promote etoposide resistance.

Authors:  Phi M Do; Lakshman Varanasi; Songqing Fan; Chunyang Li; Iwona Kubacka; Virginia Newman; Krishna Chauhan; Silvano Rakeem Daniels; Maurizio Boccetta; Michael R Garrett; Runzhao Li; Luis A Martinez
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

3.  Hypomethylation of DNA-binding inhibitor 4 serves as a potential biomarker in distinguishing acquired tamoxifen-refractory breast cancer.

Authors:  Yonghui Zhang; Bin Zhang; Jing Fang; Xuchen Cao
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

4.  Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity.

Authors:  Timo Quante; Benjamin Otto; Marie Brázdová; Iva Kejnovská; Wolfgang Deppert; Genrich V Tolstonog
Journal:  Cell Cycle       Date:  2012-08-21       Impact factor: 4.534

5.  Mutant p53 regulates enhancer-associated H3K4 monomethylation through interactions with the methyltransferase MLL4.

Authors:  Homa Rahnamoun; Juyeong Hong; Zhengxi Sun; Jihoon Lee; Hanbin Lu; Shannon M Lauberth
Journal:  J Biol Chem       Date:  2018-06-28       Impact factor: 5.157

Review 6.  Context is everything: extrinsic signalling and gain-of-function p53 mutants.

Authors:  Ivano Amelio; Gerry Melino
Journal:  Cell Death Discov       Date:  2020-03-23

7.  E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B.

Authors:  David Engelmann; Deborah Mayoli-Nüssle; Christian Mayrhofer; Katharina Fürst; Vijay Alla; Anja Stoll; Alf Spitschak; Kerstin Abshagen; Brigitte Vollmar; Sophia Ran; Brigitte M Pützer
Journal:  J Mol Cell Biol       Date:  2013-09-06       Impact factor: 6.216

Review 8.  The ID proteins: master regulators of cancer stem cells and tumour aggressiveness.

Authors:  Anna Lasorella; Robert Benezra; Antonio Iavarone
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

Review 9.  Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.

Authors:  Kanaga Sabapathy; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2017-09-26       Impact factor: 66.675

10.  Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.

Authors:  M T Branham; E Campoy; S Laurito; R Branham; G Urrutia; J Orozco; F Gago; R Urrutia; M Roqué
Journal:  Breast Cancer Res Treat       Date:  2015-11-27       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.